ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Alvontech

Alvontech (ALVO)

11.91
-0.20
(-1.65%)
Closed December 21 4:00PM
11.91
0.01
(0.08%)
After Hours: 7:35PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
11.91
Bid
11.91
Ask
15.09
Volume
1,199,326
11.70 Day's Range 12.00
9.15 52 Week Range 18.00
Market Cap
Previous Close
12.11
Open
11.89
Last Trade
70
@
12.5
Last Trade Time
Financial Volume
$ 14,280,645
VWAP
11.9072
Average Volume (3m)
96,259
Shares Outstanding
301,940,000
Dividend Yield
-
PE Ratio
-6.51
Earnings Per Share (EPS)
-1.83
Revenue
93.38M
Net Profit
-551.73M

About Alvontech

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases. Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Headquarters
Luxembourg City, Luxembourg, Lux
Founded
-
Alvontech is listed in the Coml Physical, Biologcl Resh sector of the NASDAQ with ticker ALVO. The last closing price for Alvontech was $12.11. Over the last year, Alvontech shares have traded in a share price range of $ 9.15 to $ 18.00.

Alvontech currently has 301,940,000 shares outstanding. The market capitalization of Alvontech is $3.66 billion. Alvontech has a price to earnings ratio (PE ratio) of -6.51.

ALVO Latest News

Alvotech Reports Financial Results for the First Nine Months of 2024

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first...

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024

REYKJAVIK, Iceland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

REYKJAVIK, Iceland and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

REYKJAVIK, Iceland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients...

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

REYKJAVIK, Iceland, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously...

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

REYKJAVIK, Iceland, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to Entyvio®Sales of Entyvio (vedolizumab) were about $5.4...

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

REYKJAVIK, Iceland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients...

H&R Block Shares Surge 10% on Profit and Dividend Boost, Applied Materials Drops 3% Despite Strong Earnings, Latest in Earnings

H&R Block (NYSE:HRB) – The tax preparation services company reported fourth-quarter fiscal revenue of $1.063 billion and earnings per share of $1.89, exceeding forecasts of $1.028...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10011.9112.2511.713159312.0025436CS
4-0.175-1.4480761274312.08512.2511.268721211.74692659CS
120.494.2907180385311.4213.39.159625912.36537881CS
26-1.59-11.777777777813.513.799.1510192512.14554229CS
521.1610.790697674410.75189.1516967313.81522782CS
1562.4125.36842105269.5185.211435512.16048572CS
2602.4125.36842105269.5185.211435512.16048572CS

ALVO - Frequently Asked Questions (FAQ)

What is the current Alvontech share price?
The current share price of Alvontech is $ 11.91
How many Alvontech shares are in issue?
Alvontech has 301,940,000 shares in issue
What is the market cap of Alvontech?
The market capitalisation of Alvontech is USD 3.66B
What is the 1 year trading range for Alvontech share price?
Alvontech has traded in the range of $ 9.15 to $ 18.00 during the past year
What is the PE ratio of Alvontech?
The price to earnings ratio of Alvontech is -6.51
What is the cash to sales ratio of Alvontech?
The cash to sales ratio of Alvontech is 38.47
What is the reporting currency for Alvontech?
Alvontech reports financial results in USD
What is the latest annual turnover for Alvontech?
The latest annual turnover of Alvontech is USD 93.38M
What is the latest annual profit for Alvontech?
The latest annual profit of Alvontech is USD -551.73M
What is the registered address of Alvontech?
The registered address for Alvontech is 9, RUE DE BITBOURG, LUXEMBOURG CITY, LUXEMBOURG, L-1273
What is the Alvontech website address?
The website address for Alvontech is www.alvotech.com
Which industry sector does Alvontech operate in?
Alvontech operates in the COML PHYSICAL, BIOLOGCL RESH sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
$ 0.4603
(-71.41%)
27.91M
MTEMMolecular Templates Inc
$ 0.1502
(-57.09%)
8.75M
PRFXPainReform Ltd
$ 5.15
(-53.85%)
2.94M
GALTGalectin Therapeutics Inc
$ 1.03
(-48.50%)
9.27M
BCABBioAtla Inc
$ 0.6923
(-41.82%)
6.25M
EDBLEdible Garden AG Inc
$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
$ 80.55
(8.54%)
281.23M

ALVO Discussion

View Posts
Monksdream Monksdream 2 months ago
ALVO new 52 week high
👍️0
Monksdream Monksdream 11 months ago
ALVO new 52 week high
👍️0
Monksdream Monksdream 11 months ago
ALVO new 52=week high
👍️0
Liquid_Bull Liquid_Bull 2 years ago
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
April 13 2023 - 08:45PM
GlobeNewswire Inc

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA’s reinspection of the company’s Reykjavik facility that concluded on March 17, 2023, must be satisfactorily resolved before the application can be approved. No other deficiencies in the application were noted by the FDA. Alvotech provided the FDA comprehensive responses to the inspection observations on April 3, 2023, and is awaiting communication from the agency assessing those responses.
Alvotech’s second BLA for AVT02, which contains data to support approval as a biosimilar and additional information supporting potential interchangeability designation – remains under review by the FDA, with a Biosimilar User Fee Amendment (BsUFA) goal date of June 28, 2023. Satisfactory outcome of the facility reinspection remains the key requirement for approval.

“We look forward to working with the FDA to resolve any outstanding issues identified in the reinspection,” said Robert Wessman, Chairman and CEO of Alvotech. “We are committed to manufacturing AVT02 for patients in the United States, especially a potentially differentiated Humira biosimilar that provides a high-concentration formulation and is interchangeable.”

About AVT02
AVT02 is a monoclonal antibody and has been approved as a biosimilar to Humira® (adalimumab) in the 27 EU member countries, Norway, Lichtenstein, Iceland, the UK, Switzerland, Canada, Australia and Saudi Arabia. It is currently marketed in sixteen countries in Europe and in Canada. Dossiers are under review in multiple countries, including in the United States.

About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
👍️0
Liquid_Bull Liquid_Bull 2 years ago
Just to be clear the company name is ALVOTECH not alvoNtech which was an error while creating the board. I will fix it asap. The stock symbol is ALVO
👍️0
Liquid_Bull Liquid_Bull 2 years ago
Alvotech

https://www.alvotech.com/

We have a deep appreciation for the positive impact biologic medicines have had on health care. From insulin to vaccines to monoclonal antibody cancer therapies, biologic medicines are revolutionizing the way we treat diseases and improve patient lives.

It is our aim to broaden the availability of these important biologic medicines to patients around the world by developing and manufacturing high-quality, cost-competitive biosimilars.

Our commitment to the promise of biosimilars is foundational to our approach, our culture and the strong sense of purpose that inspires us to work smarter and faster towards this mission.

We are driven by passion - if there is a proven biologic medicine, we believe it should be accessible to all patients in need.
👍️0

Your Recent History

Delayed Upgrade Clock